Literature DB >> 31079799

Immunotherapy in Ovarian Cancer.

Weimin Wang1, Janice Rebecca Liu2, Weiping Zou3.   

Abstract

The phenotype and functionalities of the major immune cell subsets including myeloid cells, macrophages, dendritic cells, and T cells are altered in the ovarian cancer microenvironment. Immunosuppressive networks including inhibitory B7 family members and regulatory T cell-associated adenosine pathway have been defined in human ovarian cancer. In this review, the authors integrate emerging information on immunosuppressive mechanisms and T cell phenotype and discuss strategies of immunotherapeutic and vaccine regimens. Finally, crucial points regarding design of immuno-oncology clinical trials are reviewed.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adoptive T-cell transfer; Cancer vaccine; Checkpoint blockade; Immunotherapy; Ovarian cancer

Mesh:

Substances:

Year:  2019        PMID: 31079799      PMCID: PMC7017862          DOI: 10.1016/j.soc.2019.02.002

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  78 in total

Review 1.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

2.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J A Ledermann; F A Raja; C Fotopoulou; A Gonzalez-Martin; N Colombo; C Sessa
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

3.  Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.

Authors:  Aude G Chapuis; John A Thompson; Kim A Margolin; Rebecca Rodmyre; Ivy P Lai; Kaye Dowdy; Erik A Farrar; Shailender Bhatia; Daniel E Sabath; Jianhong Cao; Yongqing Li; Cassian Yee
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

4.  Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.

Authors:  Kunle Odunsi; Junko Matsuzaki; Julia Karbach; Antje Neumann; Paulette Mhawech-Fauceglia; Austin Miller; Amy Beck; Carl D Morrison; Gerd Ritter; Heidi Godoy; Shashikant Lele; Nefertiti duPont; Robert Edwards; Protul Shrikant; Lloyd J Old; Sacha Gnjatic; Elke Jäger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-27       Impact factor: 11.205

Review 5.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

6.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

Authors:  P Brossart; S Wirths; G Stuhler; V L Reichardt; L Kanz; W Brugger
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

Authors:  Weimin Wang; Ilona Kryczek; Lubomír Dostál; Heng Lin; Lijun Tan; Lili Zhao; Fujia Lu; Shuang Wei; Tomasz Maj; Dongjun Peng; Gong He; Linda Vatan; Wojciech Szeliga; Rork Kuick; Jan Kotarski; Rafał Tarkowski; Yali Dou; Ramandeep Rattan; Adnan Munkarah; J Rebecca Liu; Weiping Zou
Journal:  Cell       Date:  2016-04-28       Impact factor: 41.582

8.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.

Authors:  Wanqiang Sheng; Martin W LaFleur; Thao H Nguyen; Sujun Chen; Ankur Chakravarthy; Jake Ryan Conway; Ying Li; Hao Chen; Henry Yang; Pang-Hung Hsu; Eliezer M Van Allen; Gordon J Freeman; Daniel D De Carvalho; Housheng Hansen He; Arlene H Sharpe; Yang Shi
Journal:  Cell       Date:  2018-06-21       Impact factor: 41.582

9.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

Authors:  Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos
Journal:  Oncotarget       Date:  2016-03-22

10.  Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.

Authors:  Dongjun Peng; Ilona Kryczek; Nisha Nagarsheth; Lili Zhao; Shuang Wei; Weimin Wang; Yuqing Sun; Ende Zhao; Linda Vatan; Wojciech Szeliga; Jan Kotarski; Rafał Tarkowski; Yali Dou; Kathleen Cho; Sharon Hensley-Alford; Adnan Munkarah; Rebecca Liu; Weiping Zou
Journal:  Nature       Date:  2015-10-26       Impact factor: 49.962

View more
  11 in total

Review 1.  Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma.

Authors:  S Leenen; M Hermens; P J de Vos van Steenwijk; R L M Bekkers; E M G van Esch
Journal:  Cancer Immunol Immunother       Date:  2021-01-07       Impact factor: 6.968

2.  Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations.

Authors:  Mitchell Acland; Noor A Lokman; Clifford Young; Dovile Anderson; Mark Condina; Chris Desire; Tannith M Noye; Wanqi Wang; Carmela Ricciardelli; Darren J Creek; Martin K Oehler; Peter Hoffmann; Manuela Klingler-Hoffmann
Journal:  Cancers (Basel)       Date:  2022-06-02       Impact factor: 6.575

3.  Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.

Authors:  Lixing Chen; Yali Zhai; Yisheng Wang; Eric R Fearon; Gabriel Núñez; Naohiro Inohara; Kathleen R Cho
Journal:  Cancer Res       Date:  2021-04-16       Impact factor: 12.701

4.  Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype.

Authors:  Xue Hao; Bo Zhao; Wei Zhou; Heng Liu; Takeshi Fukumoto; Dmitry Gabrilovich; Rugang Zhang
Journal:  iScience       Date:  2020-12-30

Review 5.  Immunotherapy Advances for Epithelial Ovarian Cancer.

Authors:  Erin G Hartnett; Julia Knight; Mackenzy Radolec; Ronald J Buckanovich; Robert P Edwards; Anda M Vlad
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

6.  Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers.

Authors:  Mengjing Cui; Qianqian Xia; Xing Zhang; Wenjing Yan; Dan Meng; Shuqian Xie; Siyuan Shen; Hua Jin; Shizhi Wang
Journal:  Front Genet       Date:  2022-01-11       Impact factor: 4.599

7.  MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer.

Authors:  Jun Xiong; Xiaoju He; Yuanyuan Xu; Wei Zhang; Fen Fu
Journal:  J Ovarian Res       Date:  2021-06-02       Impact factor: 4.234

Review 8.  Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites.

Authors:  Yueqing Gong; Jianling Yang; Yan Wang; Lixiang Xue; Junjie Wang
Journal:  Int J Cancer       Date:  2020-04-25       Impact factor: 7.396

Review 9.  Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.

Authors:  Chang Yang; Bai-Rong Xia; Zhao-Cong Zhang; Yong-Jian Zhang; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

10.  Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer.

Authors:  Katharina Dötzer; Friederike Schlüter; Franz Edler von Koch; Christine E Brambs; Sabine Anthuber; Sergio Frangini; Bastian Czogalla; Alexander Burges; Jens Werner; Sven Mahner; Barbara Mayer
Journal:  Biomedicines       Date:  2021-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.